The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSUMM.L Share News (SUMM)

  • There is currently no data for SUMM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Small caps round-up: Tower Resources, Global Petroleum, Norseman Gold

Wed, 24th Feb 2010 09:44

Shares in Global Petroleum and Tower Resources slumped after the companies reported that the Avivi-1 well in Uganda had reached its total depth without showing any oil.Avivi-1 is owned by Tower, while Global has an option to earn a 25% interest in the licence, by funding 25% of the costs.'Electric logging operations are underway and a full statement will be released once these have been completed,' the companies said.Norseman Gold, which mines for the precious metal in Australia, saw profits fall in the six months to December 31 as production missed targets.Pre-tax profits for the period totalled A$680,000, a 24% fall from A$897,000 over the same period the previous year, as revenue fell to $37.95m from A$42.83m.Lower than expected production for the period means the company now expects to produce 75,000 to 80,000 tonnes for the full year, compared with a previous estimate of 80,000 to 85,000 tonnes.Greek leisure resort developer and renewable energy company Minoan Group said it is in 'substantive discussions regarding potential transactions in the tourism and leisure sector' thatm if consummated, would provide strong cash flows and profit growth.The company, which currently has zero revenues, saw losses more than halve to £0.92m in the year to 30 September 2009 from £2.49m in the 18 months to 30 September 2008.Drug discovery company Summit said that after its £5.4m fund raising in December it had a positive cash position of £6m at the end of January. The company said it is 'funded well beyond the point where it anticipates receiving significant milestone payments from our partners' and that the cash surplus would allow it to accelerate the development of Summit's innovative iminosugar technology platform.
More News
24 Feb 2020 10:52

Summit Therapeutics Delists In London As Focus Shifts To US

Summit Therapeutics Delists In London As Focus Shifts To US

Read more
24 Jan 2020 12:49

Summit Therapeutics Chief Operating & Medical Officer Roblin Resigns

Summit Therapeutics Chief Operating & Medical Officer Roblin Resigns

Read more
23 Jan 2020 16:47

Summit Gets More Funding For C. Difficile Infection Treatment

Summit Gets More Funding For C. Difficile Infection Treatment

Read more
24 Dec 2019 10:27

Summit Therapeutics Shuffles Board After Raising USD50 Million

Summit Therapeutics Shuffles Board After Raising USD50 Million

Read more
24 Dec 2019 09:09

Summit Therapeutics raises $40m, completes board restructuring

(Sharecast News) - Antibiotic innovation company Summit Therapeutics raised $50.0m on Tuesday by way of a subscription and placing of new ordinary shares and warrants.

Read more
17 Dec 2019 13:20

Summit Therapeutics Reports Decrease In Revenue In Third Quarter

Summit Therapeutics Reports Decrease In Revenue In Third Quarter

Read more
6 Dec 2019 13:34

Summit Therapeutics Plans Wholesale Changes As It Raises Cash

Summit Therapeutics Plans Wholesale Changes As It Raises Cash

Read more
6 Dec 2019 08:56

Summit Therapeutics raising $50m, plans to delist from AIM

(Sharecast News) - Antibiotic innovation company Summit Therapeutics announced a proposed fundraising of about $50m through a subscription and placing of new ordinary shares and warrants to existing investors on Friday, which would be subject to certain shareholder approvals being obtained and certain customary closing conditions being satisfied.

Read more
11 Oct 2019 12:53

Summit Therapeutics Sinks To Interim Loss On Ezutromid Discontinuation

Summit Therapeutics Sinks To Interim Loss On Ezutromid Discontinuation

Read more
7 Oct 2019 13:23

Summit Therapeutics Posts Explanation For Ridinilazole Trial In C Diff

Summit Therapeutics Posts Explanation For Ridinilazole Trial In C Diff

Read more
3 Oct 2019 14:23

Summit Therapeutics Reports Positive Ridinilazole Trial Results

Summit Therapeutics Reports Positive Ridinilazole Trial Results

Read more
17 Jul 2019 13:48

Summit Therapeutics New Antibiotic Shows Potential Against Gonorrhoea

(Alliance News) - Summit Therapeutics PLC on Wednesday highlighted the potential of its preclinical new class antibiotic, SMT-571, to treat gonorrhoea, at the STI & HIV World Congress in said

Read more
12 Jun 2019 13:54

Summit Therapeutics Narrows First Quarter Loss As Expenses Drop

(Alliance News) - Summit Therapeutics on Wednesday said its loss narrowed in its financial first quarter due to an increase in other operating income and a reduction in operating which develops a

Read more
15 Apr 2019 11:26

Summit Therapeutics DDS-04 Series Antibiotic Cures Infection In Study

LONDON (Alliance News) - Summit Therapeutics PLC on Monday presented proof of concept data for its DDS-04 series of antibiotics targeting Enterobacteriaceae, a family of bacteria that cause severe

Read more
15 Apr 2019 10:16

Summit Therapeutics upbeat on latest DDS-04 data

(Sharecast News) - Antibiotic innovation firm Summit Therapeutics reported on in vivo proof-of-concept data for the DDS-04 series of new mechanism antibiotics targeting enterobacteriaceae on Monday, having presented them at the 29th European Congress of Clinical Microbiology and Infectious Diseases in Amsterdam.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.